Bionova Pharmaceuticals Ltd. has identified heteroaromatic carboxamide compounds acting as Bruton tyrosine kinase (BTK) and BTK (C481S mutant) inhibitors reported to be useful for the treatment of asthma, cancer, graft-vs.-host disease, inflammatory bowel disease, psoriasis, thrombotic thrombocytopenic purpura, rheumatoid arthritis and autoimmune thyroiditis, among others.